Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | Datamonitor Reports | Pipeline and Commercial Insight: Hepatitis C - High unmet need drives rapid innovation

Pipeline and Commercial Insight: Hepatitis C - High unmet need drives rapid innovation

The Hepatitis C market was worth $2.3 billion in 2007, declining at a CAGR of -2.8% from 2004-2007. Despite this recent slump, Datamonitor forecasts sales to grow to $4.5 billion by 2017, driven primarily by the launch of the new protease inhibitors. The US and EU will remain the largest markets, generating $1.9 billion and $1.7 billion respectively in 2017.

An overview of the current Hepatitis C market and its key players

In-depth analysis of Phase II and III clinical development compounds and comprehensive overview of Phase I drugs

Epidemiological dynamics of Hepatitis C in the six major markets are discussed along with unmet needs

10 year sales forecasts for marketed and six pipeline drugs

Given its large patient potential and significant unmet needs, the Hepatitis C market has attracted considerable interest from companies with a strong presence in infectious diseases. The HCV pipeline is therefore very active and consists of drugs with various mechanisms of action.

Several strategies are being explored in clinical trials, including add-on therapy to the current standard of care, interferon replacement and ribavirin replacement. Of these Datamonitor believes that add-on therapy will be the most successful in the medium term.

The two most advanced pipeline candidates are Schering Plough's boceprevir and Vertex's telaprevir. Both drugs have demonstrated comparable efficacy benefits when combined with current standard of care. Datamonitor expects telaprevir to gain higher market share due to its ability to cut short the overall duration of therapy in genotype 1 patients.

Understand current and future Hepatitis C market dynamics

Gain insight into the unmet needs of HCV patients and the extent to which pipeline drugs are addressing these issues

Evaluate the Hepatitis C market forecast for existing and key pipeline drugs to 2018

Publication: 39783
Library Code: DMHC2454
Type: Report
Format: PDF & DataPack
Pages: 177

Table of Contents
Price: $15,200.00 / €10,066.96

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions